Armata Pharmaceuticals Inc. buy mixitrader
Start price
08.01.22
/
50%
€4.52
Target price
08.01.23
€10.00
Performance (%)
-7.52%
End price
22.01.22
€4.18
Summary
This prediction ended on 22.01.22 with a price of €4.18. With a performance of -7.52%, the BUY prediction for Armata Pharmaceuticals Inc. by mixitrader closed slightly in the red. mixitrader has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Armata Pharmaceuticals Inc. | 0.741% | 0.741% | 164.078% |
iShares Core DAX® | -3.033% | -0.013% | 11.953% |
iShares Nasdaq 100 | -3.554% | -2.546% | 30.128% |
iShares Nikkei 225® | -3.938% | 2.183% | 11.741% |
iShares S&P 500 | -1.517% | -0.882% | 25.752% |
According to mixitrader what are the pros and cons of Armata Pharmaceuticals Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
High dividend yield expected
Good rating
Standard Investments for future growth
Valuable balance sheet
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Capable Management
Good culture
Innovative
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Top 10 in its market
Small cyclical dependencies
Known brand
Future proof or reliable business model
Cons
Comments by mixitrader for this prediction
In the thread Armata Pharmaceuticals Inc. diskutieren
Buy mit Kursziel 10,0
In the thread Trading Armata Pharmaceuticals Inc.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by mixitrader for Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.82
11.05.24
11.05.24
€4.00
11.05.25
11.05.25
-17.02%
19.05.24
19.05.24
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group